Analysis Teva Is Hurting Its Chances of Emerging From the Ruins

Now more than ever the pharmaceutical giant needs a CEO who will rehabilitate the company - but with a package worth $9.2 million, the temporary CEO has no incentive to give up his job

comments Print
“A terrorist preventing the appointment of a permanent CEO is on the Teva board of directors,” said Benny Landa, the activist investor in Teva Pharmaceutical Industries, in an interview over the weekend.